![Charles C. Clark](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Charles C. Clark
Keine laufenden Positionen mehr
Profil
Charles C.
Clark worked as a Director at CirculoGene Theranostics, Inc. and as an Executive Vice President-Corporate Strategies at Caremark Rx, Inc.
Ehemalige bekannte Positionen von Charles C. Clark
Unternehmen | Position | Ende |
---|---|---|
Caremark Rx, Inc.
![]() Caremark Rx, Inc. Medical/Nursing ServicesHealth Services Caremark Rx, Inc. provides pharmaceutical and prescription benefit program services. The company primarily sponsors of health benefit plans and individuals located throughout the United States. The company was established in 1993 and is headquartered in Nashville, TN. | Corporate Officer/Principal | 23.03.2007 |
CirculoGene Theranostics, Inc.
![]() CirculoGene Theranostics, Inc. Medical SpecialtiesHealth Technology CirculoGene Theranostics LLC operates as a molecular diagnostics company. It develops test for deoxyribonucleic acid liquid biopsies. It offers next-generation sequencing (NGS) method to provide full genomic load analysis, enabling accurate data to help clinicians and their patients. The company was founded by Chen-Hsiung Yeh in 2015 and is headquartered in Birmingham, AL. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Caremark Rx, Inc.
![]() Caremark Rx, Inc. Medical/Nursing ServicesHealth Services Caremark Rx, Inc. provides pharmaceutical and prescription benefit program services. The company primarily sponsors of health benefit plans and individuals located throughout the United States. The company was established in 1993 and is headquartered in Nashville, TN. | Health Services |
CirculoGene Theranostics, Inc.
![]() CirculoGene Theranostics, Inc. Medical SpecialtiesHealth Technology CirculoGene Theranostics LLC operates as a molecular diagnostics company. It develops test for deoxyribonucleic acid liquid biopsies. It offers next-generation sequencing (NGS) method to provide full genomic load analysis, enabling accurate data to help clinicians and their patients. The company was founded by Chen-Hsiung Yeh in 2015 and is headquartered in Birmingham, AL. | Health Technology |